Clinical Research Directory

Inclusion Criteria: * Aged 18 to 75 years, regardless of gender. * Pathologically confirmed extranodal NK/T-cell lymphoma (ENKTCL). * Ann Arbor stage I-II disease with primary lesion located in the nasal cavity or upper aerodigestive tract (UADT). * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. * Treatment-naïve patients with no prior radiotherapy, chemotherapy or targeted therapy. * Adequate major organ function as follows: * Hematopoietic function: absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelet count (PLT) ≥100×10⁹/L, hemoglobin (Hb) ≥90 g/L. * Hepatic function: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN), alanine transaminase (ALT) / aspartate transaminase (AST) ≤2.5×ULN. * Renal function: serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance rate ≥60 mL/min. * Cardiac function: left ventricular ejection fraction (LVEF) ≥50%. * Expected overall survival ≥6 months. * Voluntarily sign the written informed consent form. Exclusion Criteria: * Non-nasal type ENKTCL, or primary lesions outside the upper aerodigestive tract (UADT), including skin, gastrointestinal tract, lung and other sites. * Patients with Ann Arbor stage III-IV disease. * Central nervous system involvement. * History of prior malignant tumors, excluding non-melanoma skin cancer or cervical carcinoma in situ cured for more than 5 years. * Active infections, including active hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infection. * Severe complications, such as uncontrolled diabetes mellitus and severe cardiopulmonary diseases. * Pregnant or lactating women. * Hypersensitivity or contraindication to any investigational drugs in this study. * Concurrent participation in other interventional clinical trials.